ABSTRACT The binding of [20-3H] Tumor-promoting agents are a class of weakly carcinogenic or noncarcinogenic compounds that enhance the formation of tumors when repeatedly applied to mouse skin that has been previously treated with a subcarcinogenic dose ofa carcinogen. This process is known as the two-stage model (initiation and promotion) for the development of skin tumors in mice (1, 2). A wide range of chemical compounds have been shown to have promoting activity (3). Phorbol 12-myristate 13-acetate (PMA; 12-O-tetradecanoylphorbol 13-acetate) is the most potent tumor promoter among the 25 phorbol 12,13-diesters isolated from croton oil. The results of investigations of the metabolism of phorbol esters and their chemical requirements for promotion have been discussed (3-5).
Tumor-promoting agents are a class of weakly carcinogenic or noncarcinogenic compounds that enhance the formation of tumors when repeatedly applied to mouse skin that has been previously treated with a subcarcinogenic dose ofa carcinogen. This process is known as the two-stage model (initiation and promotion) for the development of skin tumors in mice (1, 2) . A wide range of chemical compounds have been shown to have promoting activity (3) . Phorbol 12-myristate 13-acetate (PMA; 12-O-tetradecanoylphorbol 13-acetate) is the most potent tumor promoter among the 25 phorbol 12,13-diesters isolated from croton oil. The results of investigations of the metabolism of phorbol esters and their chemical requirements for promotion have been discussed (3) (4) (5) .
Tumor promoters have pleiotropic effects and modify many cellular and biochemical responses (3, 6, 7) . It is not known which of these are specific to tumor promotion and which represent secondary events. In the past decade, one of the main strategies for examining the specificity of responses has been correlating the degree of response to graded doses of the promoters or their nonpromoting derivatives. Because correlation does not imply causation, however, this approach has not greatly increased our understanding of the actual mechanism of promotion. Thus, the critical events in tumor promotion remain unresolved. Recently, it has been reported that promotion can be clearly divided into two stages (8) .
Current evidence suggests that the primary interaction of PMA is with the cell surface (9) (10) (11) . Attempts have also been made to identify specific binding sites for phorbol ester tumor promoters in several tissues (12, 13) , including mouse skin (14) . Investigations using the phorbol derivative [20-3H]phorbol LT, 13- In many types ofcells (16) (17) (18) , the internalization of a ligandreceptor complex is preceded by surface clustering of receptors into specific regions of the plasma membrane. This phenomenon has been shown to be prevented at lower temperatures (18) amine or cadaverine (18) (19) (20) . As shown in Fig. 1 (Fig. 3) . However, the inhibitory effect of cadaverine was transient and only delayed the time of down regulation. A major loss of radioactive label occurred at 45-60 min in the presence ofcadaverine in contrast to 20-45 min in the absence ofcadaverine (see Fig. 1 ). The reason for this insensitivity of the epidermal cells to cadaverine after 45 min is unknown. In another experiment, the down regulation in cells after 30 min ofexposure at 37°C to 10 mM methylamine or 0.1 mM dansylcadaverine was examined. The dependence of specific [3H]PDB binding on the concentration of ligand was also determined (Fig. 4A) . The specific [3H]PDB binding to the intact cells increased with increasing concentrations ofthe ligand and appeared to be saturable. Scatchard analysis of the binding data (Fig. 4B ) indicated a slope corresponding to KD = 10 nM, in fair agreement with values reported for the 100,000 X g pellet from mouse skin (14) and chicken embryo fibroblasts (12 (9) (10) (11) suggest that the primary interaction of phorbol ester tumor promoters is with the cell surface. In view of the-fact that phorbol ester promoters have multifaceted effects in various biological systems (3, 6, 7) , the specificity of this interaction has been questioned. Because of similarities between the biochemicalchanges induced by epidermal growth factor and by PMA (10) , the growth factor receptor was predicted to be a candidate for PMA interaction. However, kinetic studies of the inhibition of growth factor binding by PMA have resulted in variable data (10, 11, (28) (29) (30) , and the results to date have shown that the inhibition is not due to direct competition ofPMA for the growth factor receptor. This report demonstrates specific binding of phorbol esters and related promoters to intact epidermal cells. These results are consistent'with the recent report (14) that phorbol ester promoters have specific binding sites in the 100,000 X g particulate fraction from mouse skin.
The rapid down regulation of bound [3H]PDB observed in these cells may be a general mechanism that also takes place in other cell types. A similar down regulation of [3H]PDB was observed in human promyelocytic leukemia cells (31) and in a mouse epidermal cell line (unpublished results). Because PDB is not metabolized or inactivated by epidermal cells in 1 hr (unpublished results), the apparent loss of [3H]PDB-binding is not due to its metabolism. The loss of bound [3H]PDB appears to result from conformational changes in the binding sites. Also, after down regulation, the measured radioactivity associated with the cells may be a consequence of interiorized. ligand-receptor complexes. In addition, our data also show that PDB-induced down regulation in epidermal cells appears to be specific to the class of biologically active phorbol esters; prior exposure of cells to PMA, but not to phorbol, resulted in a reduction in the number of binding sites for [3H]PDB. It should be remembered that phorbol does not compete 'for [3H]PDB binding sites.
The down regulation of the binding of several hormones (16) (17) (18) (19) (20) 30) , including epidermal growth factor (10, 28-30, 32, 33) , occurs via a process of internalization ofhormone-receptor complexes. The down regulation of [3H]PDB binding sites is prevented at 40C in a fashion similar to that of several other hormones. (18, 28, 29) that have been shown to be internalized by a receptor uptake process. Because internalization occurs with epidermal growth factor and several hormones, it may be the case with phorbol esters but we do not have any evidence for this. The process ofinternalization in some cell types (18) (19) (20) but not in others (34) is prevented by alkylamines such as methylamine and cadaverine. Our data show that the down regulation of [3H]PDB binding in epidermal cells is not prevented by these agents.
The loss ofspecific [3H]PDB binding in epidermal cells is one ofthe most rapid examples ofdown regulation thus far observed. The physiological significance of such a rapid loss of bound
[3H]PDB from these cells has yet to be determined. Also, 1-hr exposure ofepidermal cells to PMA (followed by removal of the PMA from the medium) was sufficient to stimulate DNA synthesis and ornithine decarboxylase activity in a manner similar to that produced by long exposure to PMA (35) . Thus, the observed down regulation may be a regular feature occurring when cells are exposed to phorbol diesters.
Despite the difficulties in making measurements at 37°C due to the rapid down regulation of specific (1981) duced by PMA (22) (23) (24) , were potent inhibitors of [3H]PDB binding. Naturally occurring promoters other than the phorbol esters may therefore initiate similar biochemical responses by binding to the same sites. DHT-B, a derivative of teleocidin B isolated from the mycellia of. Streptomyces 2A 1563 (36) , is nearly as potent as PMA in inducing tumors in mouse skin. Tumor promoters such as anthralin and chrysarobin, which are structurally unrelated to phorbol ester promoters, did not compete with [3H]PDB. Thus, these compounds may have different sites of action than PDB. The possibility of promotion by a different mechanism by these agents cannot be ruled out. Furthermore FA-or RA-induced inhibition of tumor promotion (25) (26) (27) is not mediated through alterations in the phorbol ester binding sites. Our data also suggest that RA and FA and EPP, a hyperplastic agent, do not exert their effects by binding to the binding sites that bind the phorbol esters.
Comparison of the relative abilities of various phorbol esters and related promoters to compete for [3H]PDB binding showed that PMA was a more effective competitor for the [3H]PDB sites than DPD, mezerein, or DHT-B. The relative order of these promoters for the inhibition of [3H]PDB binding was PMA > DHT-B > DPD 2 mezerein > 4-0-methyl PMA. This is also the relative order of the tumor-promoting activities of these compounds in the one-stage promotion assay in mouse skin. In summary, these results suggest that phorbol ester-receptor binding and processing, perhaps by down regulation, may be involved in tumor promotion by these agents.
